UNSPSC 51162038: Indacaterol/Glycopyrronium bromide

Indacaterol/glycopyrronium bromide is a fixed-dose combination medication for inhalation consisting of the following two active ingredients: Indacaterol maleate, an ultra-long-acting beta-adrenoceptor agonist (ultra-LABA); Glycopyrronium bromide (glycopyrrolate), a muscarinic anticholinergic.

UNSPSC 51162038 Indacaterol/Glycopyrronium bromide is a Commodity code that nominally identifies a specific inhalation drug combination used in respiratory therapy. State and local procurement activity under this code shows no relevant recent solicitations; the opportunities posted in the data set are unrelated to this pharmaceutical product. The Seminole County naloxone and safe drug deactivation procurement, the Tucson Fire Department's BLS/ALS pharmaceuticals solicitation, and the Pinellas County drug standards quote are each tagged to different UNSPSC codes and address distinct product categories—emergency overdose reversal, emergency medical supplies, and forensic reference materials respectively. No state or local purchasing bodies have posted opportunities specifically seeking indacaterol/glycopyrronium combinations within the recent activity window.

Indacaterol/glycopyrronium bromide procurement does not appear in the recent state and local marketplace under this code, and the historical database lacks signals of regular or emerging demand for this formulation from school districts, transit authorities, counties, municipalities, or state health and human services departments. Absence of activity in this Commodity category suggests either minimal adoption of this dual-agent bronchodilator in state and local health formularies, sourcing through state pharmaceutical contracts or GPOs that do not publish transaction-level opportunity notices, or a mismatch between the UNSPSC designation and actual procurement practice in the state and local market. A business development professional evaluating this code should monitor cooperative purchasing contracts managed by state pharmacy benefit managers or multistate alliances—such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic pharmaceuticals RFP posted January 20, 2026—for inclusion of this drug in broader multi-source pharmaceutical agreements, but direct solicitation under this Commodity code remains inactive as of mid-2026.